Clinical trial
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With…
NCT00144469 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00144469 |
|---|---|
| Title | A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C |
| Official title | A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a, rivavirin |
| Enrollment | 300 |
| Start date | May 1, 2002 |
| Completion | Mar 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Feb 2, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: